Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.154 USD | -1.19% | +5.08% | -85.66% |
Valuation
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Capitalization 1 | 93.37 | 66.84 | 4.474 | 3.153 | 3.56 | - | - |
Enterprise Value (EV) 1 | 93.37 | 66.84 | 4.474 | 3.153 | 3.56 | 3.56 | 3.56 |
P/E ratio | -2.29 x | - | - | - | - | - | - |
Yield | - | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - | - | - |
EV / Revenue | - | - | - | - | - | - | - |
EV / EBITDA | - | - | - | - | - | - | - |
EV / FCF | - | - | - | - | - | - | - |
FCF Yield | - | - | - | - | - | - | - |
Price to Book | - | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 8.85 | 6.24 | 22.4 | 210 | 1,633 | - | - |
Reference price 2 | 10,553 | 10,710 | 199.6 | 15.02 | 2.180 | 2.180 | 2.180 |
Announcement Date | 9/20/21 | 4/15/22 | 3/30/23 | 3/22/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - |
EBIT 1 | - | -3.088 | -10.86 | -8.657 | -10.43 | -15.78 | -17.09 |
Operating Margin | - | - | - | - | - | - | - |
Earnings before Tax (EBT) | - | - | - | - | - | - | - |
Net income | -5.082 | - | - | - | - | - | - |
Net margin | - | - | - | - | - | - | - |
EPS | -4,599 | - | - | - | - | - | - |
Free Cash Flow | - | - | - | - | - | - | - |
FCF margin | - | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - |
Announcement Date | 9/20/21 | 4/15/22 | 3/30/23 | 3/22/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBIT 1 | -6.586 | -1.86 | -1.199 | -1.218 | -1.62 | -1.933 | -2.778 | -2.326 | -2.551 | -2.691 | -2.843 | -3.01 | - |
Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net income | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - |
EPS | - | - | - | - | - | - | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 5/16/22 | 8/15/22 | 11/10/22 | 3/30/23 | 5/22/23 | 8/11/23 | 11/9/23 | 3/22/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - | - |
Net Cash position | - | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
Free Cash Flow | - | - | - | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
Assets | - | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - |
Capex | - | - | - | - | - | - | - |
Capex / Sales | - | - | - | - | - | - | - |
Announcement Date | 9/20/21 | 4/15/22 | 3/30/23 | 3/22/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-85.66% | 3.56M | |
+2.48% | 42.75B | |
+47.70% | 41.61B | |
+12.03% | 41.34B | |
-8.83% | 26.59B | |
+7.99% | 25.49B | |
-22.53% | 18.12B | |
+30.71% | 12.24B | |
-1.48% | 11.76B | |
+8.76% | 11B |
- Stock Market
- Equities
- REVB Stock
- Financials Revelation Biosciences, Inc.